{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'The medical record must include a statement that written informed consent was', 'obtained before the subject entered the study and the date the written consent was', 'obtained. The authorized person obtaining the informed consent must also sign the', 'ICF.', 'Subjects must be re-consented to the most current version of the ICF(s) during their', 'participation in the study.', \"A copy of the ICF(s) must be provided to the subject or the subject's legally\", 'authorized representative.', 'A pharmacogenetics (PGx) consent form must be offered to all subjects and the', 'process must be documented, unless prohibited by local regulations.', '10.1.3.', 'Data Protection', 'Subjects will be assigned a unique identifier by the Sponsor. Any subject records or', 'datasets that are transferred to the Sponsor will contain the identifier only; subject', 'names or any information which would make the subject identifiable will not be', 'transferred.', 'The subject must be informed that his/her personal study-related data will be used by', 'the Sponsor in accordance with local data protection law. The level of disclosure must', 'also be explained to the subject.', 'The subject must be informed that his/her medical records may be examined by', 'Clinical Quality Assurance auditors or other authorized personnel appointed by the', 'Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory', 'authorities.', '10.1.4.', 'Dissemination of Clinical Study Data', 'A clinical study report (CSR) will be developed by the Sponsor at completion of data', 'analysis. This report will be a clinical and statistical integrated report, according to', 'the ICH E3 guidelines.', 'Sponsor will register the study and post study results regardless of outcome on', 'a publicly accessible website in accordance with the applicable laws and regulations.', '10.1.5.', 'Data Quality Assurance', 'All subject data relating to the study will be recorded on printed or electronic eCRF', 'unless transmitted to the Sponsor or designee electronically (eg, laboratory data).', 'The investigator is responsible for verifying that data entries are accurate and correct', 'by physically or electronically signing the eCRF.', 'The investigator must maintain accurate documentation (source data) that supports', 'the information entered in the eCRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '50', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Monitoring details describing strategy (eg, risk-based initiatives in operations and', 'quality such as Risk Management and Mitigation Strategies and Analytical Risk-', 'Based Monitoring), methods, responsibilities and requirements, including handling of', 'noncompliance issues and monitoring techniques (central, remote, or on-site', 'monitoring) are provided in the Monitoring Plan.', 'The Sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'The Sponsor assumes accountability for actions delegated to other individuals', '(eg, Contract Research Organizations).', 'Study monitors will perform ongoing source data verification to confirm that data', 'entered into the eCRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of subjects are being', 'protected; and that the study is being conducted in accordance with the currently', 'approved protocol and any other study agreements, ICH GCP, and all applicable', 'regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this', 'study must be retained by the investigator per ICH-GCP and local regulations', 'or institutional policies. No records may be destroyed during the retention period', 'without the written approval of the Sponsor. No records may be transferred to another', 'location or party without written notification to the Sponsor.', '10.1.6.', 'Source Documents', 'Source documents provide evidence for the existence of the subject and substantiate', \"the integrity of the data collected. Source documents are filed at the investigator's\", 'site.', 'Data entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained.', 'The investigator may need to request previous medical records or transfer records,', 'depending on the study. Also, current medical records must be available.', \"Source documents are original documents, data, and records from which the subject's\", 'eCRF data are obtained. These include but are not limited to hospital records, clinical', 'and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs,', 'and correspondence.', '10.1.7.', 'Study and Site Closure', 'The Sponsor designee reserves the right to close the study site or terminate the study', 'at any time for any reason at the sole discretion of the Sponsor. Study sites will be', 'closed upon study completion. A study site is considered closed when all required', 'documents and study supplies have been collected and a study-site closure visit has', 'been performed.', 'The investigator may initiate study-site closure at any time, provided there is', 'reasonable cause and sufficient notice is given in advance of the intended termination.', '51', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}